Shionogi Patent-Cliff Exposure & CMS Drug Spending Portfolio

Shionogi (US): 3 reconciled FDA prescription therapies, $405.3M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2035-01-01
2024 CMS Total Public Spend$405.3M
2024 Medicare Part D Spend$382.6M
2024 Medicaid Spend$22.7M
California HCAI SB 17 Filings2 WAC filings (max 18.0% 2-yr change)